

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Dapagliflozin for treating chronic kidney disease (review of TA775)  
[ID6411]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No equality issues raised during the scoping process.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No. However, there were equality issues raised during the original appraisal (TA775). These highlighted that: <ul style="list-style-type: none"><li>• Chronic kidney disease disproportionately affects people from Black, Asian, and minority ethnic groups and lower socioeconomic backgrounds.</li><li>• People from these groups are also more likely to have chronic kidney disease that progresses quicker to kidney failure and to die earlier.</li></ul>

- Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) differs by ethnicity and socioeconomic status.

These have been included in the draft scope. However, in the original appraisal, the committee did not consider these to be equality issues that could be resolved by the TA775 appraisal.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

**Approved by Technical Advisor (name):** Alexandra Filby

**Date:** 16/05/2024